Listening to Women : Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy
Introduction: Recent high-profile calls have emphasized that women's experiences should be considered in maternity care provisioning. We explored women's experiences of using closed-loop during type 1 diabetes (T1D) pregnancy to inform decision-making about antenatal rollout and guidance and support given to future users. Methods: We interviewed 23 closed-loop participants in the Automated insulin Delivery Among Pregnant women with T1D (AiDAPT) trial after randomization to closed-loop and ∼20 weeks later. Data were analyzed thematically. Results: Women described how closed-loop lessened the physical and mental demands of diabetes management, enabling them to feel more normal and sleep better. By virtue of spending increased time-in-range, women also worried less about risks to their baby and being judged negatively by health care professionals. Most noted that intensive input and support during early pregnancy had been crucial to adjusting to, and developing confidence in, the technology. Women emphasized that attaining pregnancy glucose targets still required ongoing effort from themselves and the health care team. Women described needing education to help them determine when, and how, to intervene and when to allow the closed-loop to operate without interference. All women reported more enjoyable pregnancy experiences as a result of using closed-loop; some also noted being able to remain longer in paid employment. Conclusions: Study findings endorse closed-loop use in T1D pregnancy by highlighting how the technology can facilitate positive pregnancy experiences. To realize fully the benefits of closed-loop, pregnant women would benefit from initial intensive oversight and support together with closed-loop specific education and training. Clinical Trial Registration number: NCT04938557.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Diabetes technology & therapeutics - 25(2023), 12 vom: 05. Dez., Seite 845-855 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lawton, Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Closed-loop |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 08.12.2023 published: Print-Electronic ClinicalTrials.gov: NCT04938557 Citation Status MEDLINE |
|---|
| doi: |
10.1089/dia.2023.0323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362896038 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362896038 | ||
| 003 | DE-627 | ||
| 005 | 20231227131706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/dia.2023.0323 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM362896038 | ||
| 035 | |a (NLM)37795883 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lawton, Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Listening to Women |b Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 08.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04938557 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Recent high-profile calls have emphasized that women's experiences should be considered in maternity care provisioning. We explored women's experiences of using closed-loop during type 1 diabetes (T1D) pregnancy to inform decision-making about antenatal rollout and guidance and support given to future users. Methods: We interviewed 23 closed-loop participants in the Automated insulin Delivery Among Pregnant women with T1D (AiDAPT) trial after randomization to closed-loop and ∼20 weeks later. Data were analyzed thematically. Results: Women described how closed-loop lessened the physical and mental demands of diabetes management, enabling them to feel more normal and sleep better. By virtue of spending increased time-in-range, women also worried less about risks to their baby and being judged negatively by health care professionals. Most noted that intensive input and support during early pregnancy had been crucial to adjusting to, and developing confidence in, the technology. Women emphasized that attaining pregnancy glucose targets still required ongoing effort from themselves and the health care team. Women described needing education to help them determine when, and how, to intervene and when to allow the closed-loop to operate without interference. All women reported more enjoyable pregnancy experiences as a result of using closed-loop; some also noted being able to remain longer in paid employment. Conclusions: Study findings endorse closed-loop use in T1D pregnancy by highlighting how the technology can facilitate positive pregnancy experiences. To realize fully the benefits of closed-loop, pregnant women would benefit from initial intensive oversight and support together with closed-loop specific education and training. Clinical Trial Registration number: NCT04938557 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Closed-loop | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Quality-of-life | |
| 650 | 4 | |a Type I diabetes | |
| 650 | 4 | |a Women's experiences | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Kimbell, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Closs, Mia |e verfasserin |4 aut | |
| 700 | 1 | |a Hartnell, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Tara T M |e verfasserin |4 aut | |
| 700 | 1 | |a Dover, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Rebecca M |e verfasserin |4 aut | |
| 700 | 1 | |a Collett, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard-Kelly, Katharine |e verfasserin |4 aut | |
| 700 | 1 | |a Hovorka, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, David |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Helen R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes technology & therapeutics |d 1999 |g 25(2023), 12 vom: 05. Dez., Seite 845-855 |w (DE-627)NLM113690495 |x 1557-8593 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:12 |g day:05 |g month:12 |g pages:845-855 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/dia.2023.0323 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 12 |b 05 |c 12 |h 845-855 | ||